- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01388062
e- Ab Sensor - Based Real-time Diagnosis of Influenza Virus
Study Overview
Status
Intervention / Treatment
Detailed Description
Since April 15 and 17, 2009, when the first two cases of novel influenza A (H1N1) infection were identified in two southern California counties, as of 12 March 2010, the virus has spread to more than 213 countries and overseas territories or communities where it has caused the deaths of at least 16713 people. Therefore, a rapid diagnosis is clinically necessary and can provide clinicians the rapid answers and make early treatment possible to reduce the complications and case-fatality rate. In addition, early diagnosis of the patients will alert parents and public health workers to prevent the contacts earlier and to limit the influenza spread.
Electrosensing antibody probing system (e- Ab sensing), which was developed for the rapid and sensitive detection of hapten, proteins or viral antigen in medical samples, will be used for analyzing the interaction kinetics between Q.anti-influenza-virus and its influenza virus antigen present in flu patients'and normal samples. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eVchip) or lateral flow through (eVsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe which specifically and selectively binds influenza-virus epitope target molecules in the test samples.
The investigators evaluate the performance of e- Ab sensor, including reproducibility, sensitivity, specificity, and cross-reaction. The potential factors which may interfere with the results would be investigated. e- Ab sensor threshold decisions must maximize its sensitivity. Therefore, the threshold value in the test group is to find the decision could have 90% sensitivity and 90% specificity. With such technique, the investigators hope to make early diagnosis and give influenza patients early treatment to reduce the complications and case-fatality rate.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan, 10051
- Recruiting
- National Taiwan University Hospital
-
Principal Investigator:
- Luan-Yin Chang, MD/PhD
-
Contact:
- Luan-Yin Chang, MD/PhD
- Phone Number: 71528 886-2-2312-3456
- Email: lychang@ntu.edu.tw
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A: The patients with confirmed or suspected infection.
- B: The patients without disease.
Exclusion Criteria:
- Patients will be excluded if they couldn't sign the consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: virus detection
|
Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti- influenza virus antibody and its antigen (influenza virus) present in patients.
The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats.
In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (influenza virus) in the test specimens.
From assessment of the electric signature of semiconductive anti- influenza virus antibodies, the eABprobe could offer sensitive detection and precise quantification of EV71.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The performance of e- Ab sensor
Time Frame: 1 Day
|
In comparison with results from direct sequencing of influenza virus, we evaluate the performance of e- Ab sensor, including reproducibility, sensitivity, specificity, and cross-reaction.
|
1 Day
|
Collaborators and Investigators
Investigators
- Principal Investigator: Luan-Yin Chang, MD,PhD, National Taiwan University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 201007054R
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza Caused by Unspecified Influenza Virus
-
SeqirusCompletedInfluenza Caused by the Novel Influenza A (H1N1) VirusAustralia
-
SeqirusCompletedInfluenza Caused by the Novel Influenza A (H1N1) VirusAustralia
-
Finnish Institute for Health and WelfareCompletedInfluenza Caused by the 2009 H1N1 Influenza VirusFinland
-
Finnish Institute for Health and WelfareCompletedInfluenza Caused by the Novel A(H1N1)v Influenza VirusFinland
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Canadian Immunization Research NetworkCHU de Quebec-Universite Laval; McGill University Health Centre/Research Institute... and other collaboratorsActive, not recruitingAvian Influenza | H5N1 Virus | H5N1 Influenza | Avian Influenza A VirusCanada
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Ab&B Bio-tech Co., Ltd.JSYither Biotech Co., LtdActive, not recruitingInfluenza | Influenza VaccineChina
-
Ab&B Bio-tech Co., Ltd.JSYither Biotech Co., LtdActive, not recruitingClinical Trial of Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and OlderInfluenza | Influenza VaccineChina
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza A Virus, H5N1 Subtype | Influenza A Virus | Influenzavirus A | H5N1 Virus | OrthomyxovirdaeUnited States
Clinical Trials on Electrosensing antibody probing system (e- Ab sensor)
-
National Taiwan University HospitalUnknownCervical Cancer | Human Papilloma Virus InfectionTaiwan
-
National Taiwan University HospitalUnknown
-
National Taiwan University HospitalUnknown
-
National Taiwan University HospitalUnknownNon-small Cell Lung Cancer (NSCLC)Taiwan
-
National Taiwan University HospitalCompleted
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingClassic Hodgkin LymphomaUnited States
-
National Cancer Institute (NCI)CompletedAnaplastic Large Cell Lymphoma, ALK-Positive | Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma | Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma | Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell LymphomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityTerminatedPrimary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedB Acute Lymphoblastic Leukemia | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Acute Lymphoblastic Leukemia in RemissionUnited States